Study finds that obesity drug semaglutide supresses appetite, food cravings and energy intake

New research presented at this year’s European Congress on Obesity (held online, 10-13 May) shows that the obesity drug semaglutide reduces appetite, food cravings and energy intake in people given a meal where they could eat as much as they liked. The study is by Dr. Dorthe Skovgaard, Novo Nordisk A/S (the manufacturer of the drug), Søborg, Denmark, and colleagues.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

The information on this site is of a general nature only and is not intended to address the specific circumstances of any particular individual or entity. It is not intended or implied to be a substitute for professional advice. Read more.